Anti-Infective Agents

All Drugs and Chemicals

Antineoplastic Agents

Vitamins

Acetic Acid

Retinol acetate

Vadimezan

DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)

DMXAA

Mark McKeage

Michael Jameson

Mark Jeffery

This was a phase I study aimed at identifying safe doses of DMXAA (now known as ASA404) to be used in future combination studies with chemotherapy.

This was a multi-centre randomized, double blind study to further characterize the effect of DMXAA on QTc interval, ophthalmic safety and pharmacodynamic effects on tumour blood flow.

Patients with refractory tumors were to each undergo six doses of treatment at weekly intervals, receiving each of six doses of DMXAA (300, 600, 1200, 1800, 2400 and 3000 mg/m2)

Phase I Safety Study of DMXAA in Refractory Tumors

5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in the Treatment of Refractory Tumors: A Phase I Multicentre Doubleblind Randomized Six-Way Intrapatient Dose-Ranging Crossover Safety Study.

Antisoma Research

Chief Medical Officer

Anti-Bacterial Agents

Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2

Dr Paul Thompson

This is a phase I study aimed at identifying safe doses of DMXAA in patients with solid tumors.

This is a dose escalation study conducted at a single center in New Zealand. Patients received dimethylxanthenone acetic acid (DMXAA) IV over 20 minutes once every three weeks, up to a maximum of 12 courses.

Cohorts of 3 patients received escalated doses of DMXAA until the maximum tolerated dose (MTD) was determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose limiting toxicity.

Patients had solid tumors for which there was no standard therapy or were refractory to conventional therapy.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Phase I Safety Study of DMXAA in Refractory Tumors	NCT00856336	Refractory Tumo...	DMXAA	18 Years -	Antisoma Research
Study of DMXAA (Now Known as ASA404) in Solid Tumors	NCT00863733	Solid Tumors	DMXAA	18 Years -	Cancer Research UK
Phase I Safety Study of DMXAA in Refractory Tumors	NCT00856336	Refractory Tumo...	DMXAA	18 Years -	Antisoma Research

Spots Global Cancer Trial Database for dmxaa

Every month we try and update this database with for dmxaa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for dmxaa

Every month we try and update this database with for dmxaa cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for dmxaa cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.